Clinical Trial

One-Year Effect on Levodopa Equivalent Daily Dose of Thalamic VIM Nucleus Stimulation Compared to Subthalamic Nucleus Stimulation in Patients With Parkinson's Disease

Study acronym: VIM vs NST
Not Yet Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated April 25, 2025 (before its estimated July 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
This study compares the effects of deep brain stimulation (DBS) of the thalamic VIM nucleus versus the subthalamic nucleus (STN) on the levodopa equivalent daily dose (LEDD) in patients with Parkinson's disease. The goal is to determine whether VIM stimulation, typically used for tremor, can also reduce medication needs. It hypothesizes that STN stimulation leads to greater LEDD reduction, but VIM may offer moderate benefits in selected case
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-04-12.
Trial Details
NCT Number NCT06936254
Lead Sponsor Central Hospital, Nancy, France
Conditions Parkinson Disease (PD), Deep Brain Stimulation
Enrollment 94 participants
Start Date 2025-04-30
Primary Completion 2026-07-30 (estimated)
Study Completion 2026-09-30 (estimated)
Updated on ClinicalTrials.gov 2025-04-25